



Camcevi® (leuprolide) – New drug approval

- On May 26, 2021, [Foresee Pharmaceuticals announced the FDA approval of Camcevi \(leuprolide\)](#), for the treatment of adult patients with advanced prostate cancer.
- Camcevi is a ready-to-use 6-month subcutaneous (SC) depot formulation of leuprolide mesylate.
- Several other injectable formulations of leuprolide are currently approved for palliative treatment of prostate cancer, including: [generic leuprolide acetate](#), [Lupron Depot®](#), and [Eligard®](#).
- The efficacy of Camcevi was established in an open label, single arm study in patients with advanced prostate carcinoma. Camcevi was administered SC at a dose of 42 mg initially on day 0 and on week 24. The major efficacy outcome measure was medical castration rate, defined as achieving and maintaining serum testosterone suppression to ≤ 50 ng/dL by week 4 through week 48 of treatment.
 - Following the first injection of Camcevi, serum testosterone levels were suppressed to ≤ 50 ng/dL by week 4 (+/-7 days) in 98.5% of the patients; and from week 4 through week 48 in 97.0% of patients (95% CI: 92.2, 98.9) estimated using the Kaplan-Meier method.
 - The percentage of patients with testosterone suppression to ≤ 20 ng/dL was 69.3% on day 28.
- Warnings and precautions for Camcevi include tumor flare; hyperglycemia and diabetes; cardiovascular diseases; QT/QTc prolongation; convulsions; laboratory tests; and embryo-fetal toxicity.
- The most common adverse reactions ($\geq 10\%$) with Camcevi use were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.
- The recommended dose of Camcevi is 42 mg administered SC once every 6 months.
 - Camcevi must be administered by a healthcare provider.
- Camcevi is exclusively licensed to Accord BioPharma and the launch plans are pending. Camcevi will be available as a 42 mg injectable emulsion.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.